Amphastar Pharmaceuticals
AMPH
114 hedge funds and large institutions have $307M invested in Amphastar Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 38 reducing their positions, and 15 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 38
1.46% less ownership
Funds ownership: 44.59% → 43.13% (-1.5%)
2% less funds holding
Funds holding: 116 → 114 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
21% less capital invested
Capital invested by funds: $388M → $307M (-$80.7M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $154K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.56M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.97M |
| 3 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
+$2.28M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.47M |
| 5 |
Goldman Sachs
New York
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$12.1M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$3.07M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.59M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
-$1.33M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.22M |
AMPH Hedge Fund Activity: Q2 2018 in Review
114 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2018, worth a combined $307M — down 21% from $388M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AMPH and 13 opened new positions — a net loss of 2 holders — while 38 trimmed existing stakes and 40 added.
The largest buyer was BlackRock, adding an estimated $5.56M. The largest seller was Invesco, cutting an estimated $12.1M.
- 114 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2018, down from 116 in Q1 2018.
- Funds reported $307M of Amphastar Pharmaceuticals stock for Q2 2018, down 21% quarter-over-quarter.
- 13 funds opened new Amphastar Pharmaceuticals positions in Q2 2018 and 15 closed out, a net change of -2 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $5.56M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2018 was Invesco, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2018.